TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Cohort Study:Forecast Fracture Risk With a Serum Marker of Type 2 Diabetes in Guangzhou Community

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* (1) aged 18-65 years; (2) patients were diagnosed with type 2 diabetes based on the definition of diabetes of WHO in 1999.~Exclusion Criteria:~* 1. type 1 diabetes and other specific types of diabetes; 2. diabetes related acute complications like diabetic ketoacidosis and hyperglycemic hyperosmolar status. 3. had used drugs that is known to have effect on bone(like active vitamin D, bisphosphonate, calcitonin, estrogen receptor modulators, estrogen, thiazolidinediones); 4. suffer from diseases that is known to have effect on bone (hyperthyroidism, hypothyroidism, hyperparathyroidism, hypoparathyroidism,cushing syndrome,chronic renal failure,renal tubular acidosis,osteoporosis after gastrectomy,osteoporosis caused by liver disease,rheumatoid disease,osteoporosis induced by gastrointestinal absorption dysfunction); 5. disuse osteoporosis; 6. cannot be exposure to sunlight due to skin diseases; 7. use glucocorticoids for over 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- fracture group (Type: None): None
- non-fracture group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of D-serine as add-on Therapy in Recent-onset Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-50~* Recent onset psychosis (\< 5 years of overt psychotic symptoms)~* Able to read and understand study procedures and participant's information~Exclusion Criteria:~* Clozapine use~* Suicidal ideation~* Psychotic disorders and symptoms associated with general medical conditions or substance abuse~* BMI \> 30~* Renal impairment (history and creatin levels (\< 80 ug/L for woman and \< 97 ug/L for men))~* Hearing impairment~* Current or past (\< 6 months) enrolment in another clinical trial with the primary outcome to improve symptoms~* Pregnant or lactating women (pregnancy test)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- D-serine group (Type: EXPERIMENTAL): Oral administration of 2g D-serine per day, for 6 weeks.
- Placebo group (Type: PLACEBO_COMPARATOR): Oral administration of 2g Placebo (Mannitol) per day, for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, 18-65 years of age~* Histologically confirmed HER2-positive breast cancer with measurable lesions (according to RECIST criteria)~* Metastatic disease after first-line therapy or recurrent disease after (neo)adjuvant therapy with Herceptin and taxanes~* ECOG performance status 0-2~Exclusion Criteria:~* CNS metastases which are not well controlled~* Simultaneous treatment with sorivudine~* History of another malignancy within the last 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in-situ of the uterine cervix~* Pregnant or lactating women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients have been suspected or diagnosed with breast cancer and they have not received any treatment; It must fulfill the ethical requirements and subjects have signed an informed consent.~Exclusion Criteria:~* Pregnancy or nursing mothers; Those patients accompanied by other serious diseases such as cardiac functional insufficiency, hepatic and renal function insufficiency.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- breast cancer (Type: EXPERIMENTAL): Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
- benign breast lesions (Type: ACTIVE_COMPARATOR): Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female adult ≥18 years of age at time of enrollment.~* Women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study.~* Subject provides written informed consent prior to initiation of any study procedures.~* Understands and agrees to comply with planned study procedures.~* Agrees to the collection and storage of saliva samples per protocol.~Exclusion Criteria:~* Severe chronic liver disease~* Severe chronic kidney disease or requiring dialysis~* Pregnancy or breast feeding.~* Allergy to the study medication~* Currently taking melatonin~* Currently taking high dose (\>500 mg/day) Vitamin C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Placebo capsules will be prepared with opaque gelatin capsules, filled using methylcellulose and over-encapsulated to appear identical to interventional drug. Placebo capsules will be given orally in the same regimen as intervention (three times daily for 14 days). Capsules will be prepared by the research pharmacist and will be mailed to study subjects directly by courier. Placebo capsules will be stored at room temperature.
- Melatonin (Type: EXPERIMENTAL): Melatonin will be administered orally as a 10 mg dose three times a day for 14 days. Size 4 clear vegetable cellulose capsules containing 10 mg melatonin, microcrystalline cellulose, and rice concentrate prepared by Life Extension® will be over-encapsulated in opaque gelatin capsules. Over-encapsulation of melatonin treatments will be done by the research pharmacist and will be mailed to study subjects directly by courier. Melatonin capsules will be stored at room temperature.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immediate Weight-bearing Verses Non-Weight-bearing After Foot & Ankle Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females age 18 to 89 years~2. Undergoing foot and ankle surgery~3. Must be able to read and understand English and consent for themselves~Exclusion Criteria:~1. Diagnosed peripheral neuropathy~2. Diagnosed peripheral vascular disease~3. Documented infection to the surgical extremity~4. Previous surgery to the surgical limb~5. Laboratory abnormalities that indicate clinically significant hematologic, hepatobiliary, or renal disease which would predispose patients to poor healing and/or non-union~6. Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Immediate protected weight-bearing (Type: OTHER): Immediate protected weight-bearing
- Traditional non weight bearing (Type: OTHER): Strict non-weight-bearing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Apneic Oxygenation Including Precipitous Intubations During RSI in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The inclusion criteria for our study will include patients 18 years or older who require emergent endotracheal intubation utilizing rapid sequence intubation (RSI) in the Emergency Department with first attempt taken by a resident or attending physician working in the emergency department. This includes Emergency Medicine attending physicians and residents as well as non-Emergency Medicine rotators (e.g.., Internal Medicine residents who are rotating through the Emergency Department).~Exclusion Criteria:~* Exclusion criteria include patients who are in cardiac arrest, or if the patient received any positive pressure ventilation (i.e, BPAP, CPAP, BVM) in the emergency department before RSI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apneic Oxygenation (Type: EXPERIMENTAL): Participants receiving apneic oxygenation
- No Apneic Oxygenation (Type: NO_INTERVENTION): Participants not receiving apneic oxygenation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Epidermoid carcinoma (EC) or adenocarcinoma of the thoracic oesophagus or adenocarcinoma of the oesogastric junction (Siewert type I or II) proven histologically~* Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 after a full investigation~* Patient considered operable with a curative intent and scheduled to undergo first-line radiochemotherapy in a multidisciplinary meeting~* Age ≥ 18 years \< 75 years~* Patient with national health insurance cover and who has provided written informed consent for the clinical and biological studies.~Exclusion Criteria:~* Cancer of the cervical oesophagus (15 to 19 cm from the dental arches)~* Weight loss \> 15% at the recruitment with no improvement after nutritional support~* Serious comorbidity threatening survival in the short term~* Contra-indication for radiochemotherapy~* Other uncured malignant disease in the 5 previous years (except for in situ cervical carcinoma and treated non-melanotic skin cancers)~* Absence of effective contraception in patients (men or women) able to procreate, pregnant or breast-feeding women~* Impossibility to follow the trial~* Legal disqualification (patients in custody or under guardianship)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- Arm A: Systematic surgery (Type: EXPERIMENTAL): None
- Arm B: Surveillance and rescue surgery in cases of resectable (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological or radiographic diagnosis of a pan-invasive pituitary macroadenoma~* Pan-invasive for the purposes of the protocol will be defined as meeting each of the following 2 major criteria: (1). tumor volume greater than 20 cc at enrollment, and (2). suprasellar extension. In addition, a pan-invasive tumor must meet any one of the following 3 minor criteria, a) unresectable tumor invasion into a cavernous sinus, b) bone or bone marrow invasion into the clivus or temporal bones, or c) tumor extension in any direction unlikely to be completely removed by specifically a transphenoidal surgical approach.~* Patients who meet the two major criteria above (1 and 2) and are medically inoperable for tumor resection (due to confounding co-existing medical problems) are eligible without meeting any of the three minor criteria (a, b, or c).~* Patients should be immediately threatened for vision loss or other significant neurological impairment directly related to tumor mass effect. As such, all patients enrolled would likely benefit from tumor response (shrinkage).~* Patients must have visible tumor on imaging studies (MRI or CT)~* The patient's Zubrod performance status must be 0-3.~* Patients must be at least 18 years of age.~* Mandatory Imaging Studies: Must be done 45 or fewer days prior to :~MRI or CT scan of the brain including the entire skull base and all areas of tumor extension~Exclusion Criteria:~* Patients who are unable to undergo general anesthesia~* Patients who are unable to undergo placement of a stereotactic head frame~* Patients who are unable to provide informed consent~* Patients who are pregnant or nursing~* Patients with severe kidney dysfunction~* Patients who have contraindications to MRI, such as implanted pacemaker device~* Patients with diagnosis of pituitary carcinoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Radiation Therapy (Type: EXPERIMENTAL): Interstitial Radioactive Iodine Implants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Collaborative Assessment and Management of Suicidality With Suicidal Children (CAMS-4Kids)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* children between the ages of 5 - 11 years old, inclusive, at the time of consent;~* current suicidal ideation and/or behavior;~* resides with primary caregiver who has legal authority to consent to research participation~* client of outpatient Behavioral Health Services~* Outpatient or Mood and Anxiety Program visit scheduled at least 4 weeks from the diagnostic assessment and/or discharge from the Crisis Stabilization Unit.~Exclusion Criteria:~* the inability to understand study procedures (e.g. developmental disabilities, severe cognitive impairments, actively psychotic)~* inability of the child and/or parent to speak or read English~* current participation in weekly therapy sessions with outpatient Behavioral Health Crisis Team

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- CAMS-4Kids (Type: EXPERIMENTAL): Participants will receive up to 10 sessions of CAMS-4Kids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Medically healthy~* Male~* Right-handed aged~* 18-45 years~* BMI 17.5 to 35kg/m2.~Exclusion Criteria:~* Females~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening and at the time of dosing).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PF-06412562 3mg (Type: EXPERIMENTAL): PF-06412562 3mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID
- PF-06412562 15mg (Type: EXPERIMENTAL): PF-06412562 15mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Subject presenting with STEMI undergoing primary PCI~* Patient presents with at least 1 of the following:~* Unstable blood pressure~* Tachycardia and tissue hypoperfusion~* The need for intravenous pressor or inotropic support~* Patient presents with STEMI:~* CK-MB\>2x normal~Exclusion Criteria:~* Unwitnessed cardiac arrest~* Abnormalities of the aorta~* Recent stroke or TIA~* Mural thrombus in the left ventricle

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- IMPELLA LP 2.5 (Type: EXPERIMENTAL): None
- Intra-Aortic Balloon Pump (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the ICU after OHCA and successful CPR due to a cardiac cause~* Post anoxic coma on admission~* Ability to start study medication as soon as possible, but ultimately within 6h after OHCA via a central venous line~* Age 18 years or older~* Eligible for treatment with a target temperature management of 36⁰ C~Exclusion Criteria:~* No informed consent~* Known co-morbidity with a life expectancy of \<6 months prior to cardiac arrest~* Women aged 49 or less~* Severe cognitive impairment (documented dementia) known prior to OHCA~* Inability to insert a central venous line

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2-Iminobiotin (Type: EXPERIMENTAL): Increasing dosage of study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment with the BD-OTS device~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belfort-Dildy Obstetric Tamponade Tx (Type: None): Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues